Publications

Oncolytic Viral Therapy

May. 2022
Type I and Type II Interferon Antagonism Strategies Used by Paramyxoviridae: Previous and New Discoveries, in Comparison

Jan. 2020
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines

Oct. 2019
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma

Jan. 2018
A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model

Feb. 2017
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

May. 2015
Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models

Mar. 2014
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Jun. 2009
Genetically engineered Newcastle disease virus for malignant melanoma therapy

Nov. 2008
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

Jan. 2008
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo

Sep. 2007
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus

Virology and Vaccines

Apr. 2022
Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models

Sep. 2020
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Jul. 2020
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate

Jan. 2020
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

Dec. 2019
Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses

Aug. 2019
Moving from Empirical to Rational Vaccine Design in the 'Omics' Era

Feb. 2019
Editorial overview: Emerging viruses: interspecies transmission: Expect the unexpected

Jun. 2018
Influenza

Aug. 2017
Ten Strategies of Interferon Evasion by Viruses

Oct. 2016
A High-Resolution Look at Influenza Virus Antigenic Drift

Feb. 2016
Systems vaccinology informs influenza vaccine immunogenicity

Nov. 2015
Against the clock towards new Ebola virus therapies

Oct. 2005
Characterization of the reconstructed 1918 Spanish influenza pandemic virus

Nov. 1999
Rescue of influenza A virus from recombinant DNA

Lymphangiogenesis and Cancer

Feb. 2018
Isolation of Human Skin Lymphatic Endothelial Cells and 3D Reconstruction of the Lymphatic Vasculature In Vitro

Sep. 2014
Role of lymphatic vasculature in regional and distant metastases

Jul. 2013
Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses

Mar. 2010
Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases

Aug. 2009
Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism

Mar. 2006
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2

Nov. 2002
Molecular characterization of lymphatic endothelial cells

Ready to seek partners

Contact our team to learn more about our science and discover exciting partnership opportunities.